Table 1

Mouse models of diabetes-associated ulceration ordered in relation to the severity of wound healing impairment

NoEarly stage (2–5 days)Intermediate stage (6–10 days)Late stage (11–20 days)
1Multiple-dose alloxan
SMD 5.35 (95% CI 2.50 to 8.20)
n=6 Con, 6 Dia		Embedded ImageEmbedded ImageNOD
SMD 6.09 (95% CI 4.47 to 7.72)
n=22 Con, 18 Dia		NOD
SMD 14.59 (95% CI 4.46 to 24.71)
n=4 Con, 4 Dia
2ob/ob
SMD 3.55 (95% CI −0.07 to 7.18)
n=8 Con, 8 Dia		Multiple-dose alloxan
SMD 5.89 (95% CI 2.80 to 8.98)
n=6 Con, 6 Dia		Multiple-dose alloxan
SMD 5.84 (95% CI 2.77 to 8.91)
n=6 Con, 6 Dia
3Single-dose STZ
SMD 1.53 (95% CI 0.96 to 2.10)
n=205 Con, 205 Dia		ob/ob
SMD 4.57 (95% CI 2.1 to 7.04)
n=8 Con, 8 Dia		db/db
SMD 3.87 (95% CI 3.11 to 4.63)
n=186 Con, 215 Dia		Embedded Image
4NOD
SMD 1.47 (95% CI 0.68 to 2.27)
n=18 Con, 14 Dia		db/db
SMD 2.9 (95% CI 2.29 to 3.52)
n=212 Con, 240 Dia		Embedded ImageEmbedded ImageSingle-dose STZ
SMD 3.58 (95% CI 2.57 to 4.59)
n=114 Con, 114 Dia
5Single-dose alloxan
SMD 1.20 (95% CI 0.42 to 1.99)
n=17 Con, 17 Dia		Single-dose alloxan
SMD 2.32 (95% CI 0.63 to 4.01)
n=17 Con, 17 Dia		Single-dose alloxan
SMD 2.05 (95% CI 0.38 to 3.72)
n=17 Con, 17 Dia
6db/db
SMD 1.18 (95% CI 0.76 to 1.6)
n=206 Con, 232 Dia		Single-dose STZ
SMD 2.09 (95% CI 1.35 to 2.84)
n=196 Con, 198 Dia		Multiple-dose STZ
SMD 1.53 (95% CI 1.06 to 1.99)
n=69 Con, 76 Dia
7Multiple-dose STZ
SMD 1.16 (95% CI 0.84 to 1.47)
n=178 Con, 184 Dia		Multiple-dose STZ
SMD 1.69 (95% CI 1.27 to 2.11)
n=183 Con, 195 Dia		High-fat fed
SMD 1.34 (95% CI 0.65 to 2.03)
n=19 Con, 23 Dia
8High-fat fed
SMD 0.17 (95% CI −0.89 to 1.23)
n=19 Con, 23 Dia		High-fat fed
SMD 1.16 (95% CI 0.38 to 1.95)
n=34 Con, 38 Dia		ob/ob
No data

  • *P<0.01, significant differences as determined by pairwise comparison using Bonferroni’s correction (online supplementary table 10).

  • Con, non-diabetic control; Dia, diabetic; NOD, non-obese diabetic; SMD, standardized mean difference; STZ, streptozotocin.